There are innumerable accounts of how individual drugs have been discovered and, until recently, most textbooks of pharmacology began each chapter with a little historical account of the principal discoveries. Now there is so much pharmacology that history is crowded out. For a medical student confronted with the frightening diversity of knowledge necessary for the therapeutic use of drugs, the loss of history is a pure gain. But for a deeper student of the subject, and particularly for one who wishes to extend and improve on the existing range of remedies, the historical perspective is very valuable. The point has been brought home to me by five years of industrial experience with the specific objective of discoveringnew drugs. The methods ofdiscovery have changed and are changing so startlingly rapidly that a review of the process of discovery is no simple academic exercise but fundamental to further innovation.
Until about a century ago the discovery of new drugs was very much a matter of chance and not choice. Galenical remedies from herbals came into pharmacopeeias with very little distinction between the genuinely effective and the well reputed. Cinchona bark, foxglove leaf and ergot of rye were placed alongside remedies now forgotten, and there was no adequate means of demonstrating which were effective and which were not. The identification by Withering in 1770 of digitalis leaf as a genuine cardiotonic agent is one of the bits of history which generally persists in textbooks. It is typical of the process of recognizing a remedy when one sees one, a process still by no means obsolete.
The rise of organic chemistry in the nineteenth century presented a new range of substances which could be examined medicinally and a new means of examining substances already believed to be medicinally effective. As far as the discovery of new drugs was concerned these processes operated in almost opposite directions. In one direction compounds could be synthesized with little or no idea of their activity; such compounds often remained on chemists' shelves for many years before they were discovered to be pharmacologically active. For example, aspirin was synthesized in 1853 but its relation to salicylic acid, which led to the recognition of its possible clinical use, was not appreciated for another 36 years. Even when compounds have been synthesized for medicinal purposes their use has often not been apparent immediately.
The opposite operation with which chemists busied themselves was the identification and isolation of the active constituents present in reputedly medicinal substances. This began the great age of the isolation of alkaloids and numerous other natural products. Availability ofpure substances simplified their standardization, the study of their actions, and their therapeutic use. Sometimes it led to entirely new discoveries, as when cocaine was found to be an effective local anesthetic, and was introduced into medicine for a quite different property from that possessed by the original plant from which cocaine had been isolated.
Both the process of synthesis and the subsequent trial in medicine on the one hand, and the process of analysis of the active constituents of medicine on the other, implied a direct connexion between chemists and doctors. But by the end of the nineteenth century the new science of physiology was also developing fast. Particularly in the field of endocrinology, discoveries about normal physiological processes provided an immediate basis for therapeutic procedures. As soon as it was clear that a disease could be initiated by the failure of an endocrine organ to produce its natural hormone, the possibility of therapy by artificial provision of that hormone became self-evident. So the use of thyroid gland for the treatment of myxcedema began and some 40 years later, pure thyroxine became available for the same purpose. The connexion between the islands of Langerhans and diabetes mellitus was also known before the turn of the century. The isolation and purification of insulin was more difficult than that of thyroxine, but insulin became available by 1921 and is another early example of a drug discovered by deliberate rational choice and not as a result of chance.
At about this stage pharmacology became recognizable as a distinct and separate science even though it commonly still masqueraded under the name of materia medica. It began with the study ofsubstances which act on physiological processes in a way which is therapeutically useful; a large part of pharmacological research has always consisted of seeking new substances of this kind. One of the earliest exponents of the deliberate search for pure chemical substances was Ehrlich, memorable both for his inauguration of systematic searches through long series of chemicals and for his dogma 'corpora non agunt nisi fixata' (Ehrlich 1913) . His major innovation in the treatment of syphilis, arsphenamine or 'salvarsan', was Compound No. 606 of all those he had investigated. His earlier studies on dye-stuffs, and particularly their effect on trypanosomes, had led him to the firm conclusion that unless a drug was fixed to tissues it had no pharmacological effect on it. This dogma is probably as true as it ever was but it is often in danger of being forgotten. Possibly some pharmacological discoveries would be made more quickly today if drugs which were not fixed by tissues were disregarded.
One major contribution of pharmacology to the advance of therapeutic knowledge is the elaboration of more quantitative approaches, for the measurement both of drugs and of their effects in disease. Until about 1920 the complex organic substances which formed the active principles of many medicines were quite beyond the range of chemical or any other kind of analysis. Successive samples of the same remedy were likely to vary substantially in potency. Consequently the use of digitalis was restricted and the use of insulin exceedingly difficult. The development of methods by which the potency of therapeutically active substances could be estimated by suitable biological experiments was essential both for their practical use and as a tool in the isolation of pure active substances. Biological standardization was a triumph of its time, an example of scientific method not appreciated as it should be, and a vital stage in the evolution of therapeutics. It is startling to read in the memoir of Sir Henry Dale (Feldberg 1970 ) that he had to argue for a whole day to persuade his colleagues that insulin should be assayed by reference to a standard preparation and not by its experimental effect on an unstandardized rabbit. Also it is difficult to imagine how diabetes could be treated if successive vials of insulin differed in potency perhaps by a factor of two or three. Development of methods for the therapeutic evaluation ofrelated substances in man took much longer and is still far from complete. No rational person today doubts the need to assess by proper clinical trial whether or not a particular substance is useful in a particular disease. This is a great change of the last quarter century, not directly necessary to the discovery of new substances, but vital to the selection of the most effective.
Therapeutic innovation in the period between the wars appears to have arisen mainly from applications of physiological advances, especially in endocrinology. However, one major chemicalpharmacological advance started at least two kinds of therapeutic development. Domagk's identification in 1935 of the properties of sulphanilamide (Prontosil) as an anti-streptococcal agent active in vivo was the result of synthesizing compounds and testing them in experimental animals. It was the first clear and convincing demonstration that bacterial infections could be halted by suitable chemicals, and heralded a revolution of procedure in the treatment of many infectious diseases, from the use of sera and vaccines to that of synthesized substances. It also led, unusually rapidly, to an academic discovery by Fildes (1940) and Woods (1940) about the mode of action of sulphanilamide. Their demonstration that sulphanilamide acted by competing with the essential metabolite paraaminobenzoic acid and preventing its utilization by streptococci, initiated the concept of antimetabolites which has been so often dwelt on ever since. The practical fruit of applying the concept is smaller than might be hoped for, because it is not easy to find an antimetabolite for a particular purpose which is also free from all kinds of other, undesirable, properties. Much of the later history of the rational discovery of new drugs stems from this discovery.
The coming of war in 1939 reinforced the need for antimicrobial drugs and also brought forward some special requirements. The pressures led to many discoveries of which two are particularly relevant to my theme. One is very familiar and one, though less so, should not be allowed to lapse into oblivion. The very familiar one is, of course, penicillin, the history of which illustrates how technical advances contribute to a successful discovery. Penicillin was recognized by Fleming as a potentially useful therapeutic substance in 1929; Raistrick attempted to isolate it but failed. Chemical techniques of all kinds increased substantially in the 1930s, and the new pressures of the second world war led to a more intensive attack on the problem of isolating the substance; the attack was successful. The story is too well known to need retelling; it shows the combination of an initial chance observation and a very methodical pursuit to a successful outcome.
The discovery which is in more danger of lapsing into oblivion was that of the substance dimercaprol (or British antilewisite, BAL), the antidote to arsenical poisoning of all kinds, and the further discovery of its glucoside, once called 'BAL-INTRAV' which was abandoned because the therapeutic need for it had disappeared. The discovery of BAL-INTRAV, like that of BAL itself, was a model of therapeutic prediction justified by subsequent experimental evidence. The basis for the discovery of dimercaprol was the observation made by Peters and his associates in Oxford before the war, that arsenical compounds combine with thiol groups of proteins, and that a particularly stable compound is likely to be formed if arsenic combines with two adjacent sulphur atoms to form a cyclic structure. The war gas lewisite was an arsenical compound capable of such reactions and the treatment of lewisite poisoning was potentially very important. If a substance could be found which would form a similar stable cyclic complex with an arsenical, and if this cyclic complex could then be inactivated or excreted in some innocuous way, therapy might be possible. The simplest possible compound which could be devised, dithioethane, was not satisfactory. A very simple relative, dimercaptopropanol, was prepared and was found, although moderately toxic, to be highly effective in reversing the toxic effects of lewisite and other arsenicals in experimental animals (Peters et al. 1945) . Later it was also shown to be effective in the treatment of arsenical dermatitis in man, and in removal of other heavy metals from the body. Other chelating agents are now available but the therapeutic position of BAL is well established, and it is a good example of rational discovery of a new drug.
The efficacy of BAL is limited by its fairly high toxicity. It is a lipid-soluble, water-insoluble substance, likely to penetrate cell membranes and so carry its very reactive SH groups to numerous sites where they do more harm than good. With this in mind Danielli, then working in the Biochemistry Laboratory in Cambridge, suggested that a water-soluble derivative of BAL would have two advantages: it would not penetrate cells readily and it would be more rapidly excreted by the kidneys. His colleague Owen therefore synthesized the glucoside of dimercaprol. This compound was highly watersoluble, readily administered intravenously, about one-twentieth as toxic as BAL, and in some respects very effective for the treatment of metallic poisoning (Danielli et al. 1947) . It was inferior to BAL in that it was usually less effective if administered long after poisoning had occurred; this limitation was expected since the glucoside would not penetrate cells in pursuit of any poison that it might combine with. However, as Danielli pointed out, the shuttling of heavy metals across the cell membrane itself could readily be achieved by dimercaprol, so that the most effective therapy of all should be a combination of a small amount of the free thiol, to act as a membrane carrier, and a large amount of the glucoside to remove whatever was shuttled out of the cells. In animals it was quite practicable to demonstrate this, and in several circumstances there was no doubt that the combination of BAL and BAL-glucoside was more effective than BAL alone, thus validating the prediction made on purely theoretical grounds. It was difficult to purify BAL-glucoside and keep it stable, and it would have required substantial chemical and pharmaceutical resources to bring it to human clinical trial. By the time its efficacy was established the need for it had disappeared and these resources were never developed. Today BAL-INTRAV is probably forgotten by all except those who worked with it, but I like to remember it as an early example of rational design leading to a therapeutic agent which, at least as far as it was assessed, did all the work expected of it (Weatherall 1948) .
From here I would like to go to one of the major success stories of rational discovery which has taken place in the twenty-five years since the end of the war, the work of Hitchings and his collaborators at the Wellcome Research Laboratories, then in New York. This work is beautifully and briefly described by Hitchings himself in his Clowes Memorial Lecture (Hitchings 1969) .
'To put the program into perspective, one might have a brief look at the state of the art as it was 25 years ago. Chemotherapy was in limbo. A few empiricists were dutifully poisoning infected mice with whatever came to hand, but the main stream of scientific thought held the field beneath notice as an area devoid of intellectual challenge. It was felt that some sort of rationale might emerge in the remote future.
Meanwhile it would be better to devote oneself to scholarly pursuits without wasting much thought on practical problems. 'By the time we came on the scene, antimetabolite theory had been put forward on the basis of competition between p-aminobenzoic acid and sulfanilamide. It seemed possible that by turning the problem of chemotherapy around, and concentrating on the study of specific inhibitors and mechanisms of action, one might at the same time increase the stores of fundamental knowledge and find uses for some of the inhibitors . . . 'One of the implications of this approach is that we were uncommitted with respect to specific disease targets, but we were bound to follow wherever our thoughts and antimetabolites led us. They have led us to such diverse fields as leukemia, malaria, bacterial infections, gout, and transplantation. We believe that none of this is irrelevant to cancer chemotherapy. What I want to emphasize particularly is a method of working.'
Hitchings and his collaborators chose to work in the field of nucleoprotein biosynthesis and also that of folate metabolism. I will not discuss the chemical details involved but simply draw attention to compounds which have come out of this programme. They include thepurine analogues 6-mercaptopurine, useful as an anti-tumour agent, azathioprine, useful as an immunosuppressant, and allopurinol, useful as an inhibitor of xanthine oxidase and so in preventing the formation of uric acid in gout. They include also inhibitors of folate activity, pyrimethamine, with its selective affinity for the dihydrofolate reductase of malaria parasites, and diaveridine, a very closely related compound which has had some applications in veterinary medicine. The most recent of this group, trimethoprim, is particularly selectively bound to the dihydrofolate reductases of bacteria and so, in conjunction with sulphonamides, produces a remarkably effective two-pronged attack in the treatment of bacterial infections. This approach to the discovery of new drugs differs from the narrow objective of Peters and his colleagues in arsenical poisoning in that it was uncommitted to specific disease targets. By concentrating on a particular area of biosynthesis important to organisms of all kinds there was a good chance of finding agents which would interfere with the process selectively and that these agents would be therapeutically useful, as indeed has proved to be the case.
There is no absolute difference between the policy of rational design and the policy of synthesize and screen. Hitchings and his team synthesized large numbers of new compounds for testing in particular experimental situations or screens. However, it is also possible to operate screening systems with less rational foundations. Screens are very commonly devised as straightforward laboratory procedures in which large numbers of compounds can be tested quickly and in which existing remedies give a positive response. The validity of such a screen is seldom tested; compounds which fail to give a positive response are rejected and it is never discovered whether they are actually worthless or possess therapeutic activity which the screen has failed to show. Screens set up in this way do not require any understanding of the mechanism of action of the desired compounds, and so give no clue to the kind of compound which it is sensible to examine. Sometimes this is valuable, and gives a maximum opportunity for serendipity.
However, the operation of screens becomes mechanical and their result is very much a matter of chance not choice. Figures are frequently published to indicate how effective, or otherwise, this process may be. Bogue (1962) gave a figure of 3,000 compounds tested for every one put on the market by ICI Pharmaceuticals, and other companies seem to have similar experiences. The numerical value of the denominator may be misleading because many of the compounds made are intermediates in the synthesis of others which are finally being sought, and sometimes are not tested at all. However, it is interesting to compare the figure of 1 in 3,000 with the 1 in 960 or so for the Wellcome Research Laboratories in New York during the period when azathioprine, allopurinol and trimethoprim were being discovered. It is also interesting to note that the denominator of 3,000 tends to get bigger as time passes; recently a claim of 1 in 5,000 was put forward. The more easily available chemical compounds are beginning to be worked out, and the criteria for putting a new drug on the market are becoming more exacting. The reasons for this are well known. Tragedies have occurred because drugs had unexpected effects, and, with the advantage of hindsight, ex-periments can be devised to show that the toxic effect in man could have been predicted by suitable tests in animals. So a list has accumulated of desirable experiments in animals which should be applied to every drug before it is used in man. This is all very well up to a point, but it may be questioned whether public obsession with safety has not got a little out of proportion. Professor Kekwick has recently drawn attention to the fact that there are a hundred words in the Lord's Prayer, about a thousand words in the American Constitution and over ten million in the regulations of the American Food and Drugs Administration. Complying with these regulations is a formidable task and involves a very substantial amount of one of our scarcest of all resources, that is, highly qualified scientific manpower. The regulations are largely concerned with experiments in animals. Animals are fair, but not infallible, predictors of what will happen in man (Paget 1962 , Welch 1967 , Schein et al. 1970 . The more tests are performed on animals, the more likely a compound is to be condemned before it is ever administered to a human being. Moreover, in view of the enormous cost of toxicological investigations many more compounds are not being taken forward for any preliminary trial in man at all. We are fortunate in this country to have so enlightened a body as the Committee on Safety of Drugs, but one may note with despondency that the number of civil servants concerned in the evaluation of safety has increased about threefold as the result of the new Medicines Act. I and my colleagues have discussed this problem elsewhere (Hanley et al. 1970 ) and I do not intend to elaborate details now, but I must note that we are rapidly reaching the stage when the question arises whether it is worthwhile attempting to discover new drugs at all in view of the very large number of hurdles of dubious relevance which must be cleared before it is ever discovered whether the new substances are of any use for the purpose for which they are intended.
Sanity has a habit of prevailing in spite of, or because of, the most discouraging situations. The administrative difficulties in developing new drugs make it all the more necessary to concentrate research activities on essentials and to apply scarce resources intelligently. Any research programme today must take account of three factors: human need, scientific feasibility and commercial feasibility. As the major diseases are conquered one by one and the world becomes increasingly troubled by overpopulation and its consequences, the human needs are by no means as easy to identify as they were fifty years ago. The control of population is essential. The perpetuation of good health is fundamental. The prolongation of life other than in reasonable health is a more questionable use of limited resources. I am uneasy that well-meant attempts to modify the effects of some of the degenerative diseases of advancing years will lead more to a burdensome prolongation of life than to a contribution to human well-being. As for the second factor, scientific feasibility does not need to be stressed. It is a special case of Medawar's 'Art of the Soluble'. One of the elements of a good research programme is that it takes advantage of recent discoveries and builds upon them to develop a practical application. The third criterion, commercial feasibility, is also not negligible. The specialized techniques and high expense of developing a potential therapeutic idea into a generally useful commodity are very high and in our society as we organize it the cost can be met only from the funds generated by the sale of existing remedies. An ethical firm in possession of a potential therapeutic substance for treating a rare disease will, if it can, develop this drug for therapeutic use, but no amount of ethical conduct can alter the facts of the balance sheet, any more than a balance sheet can justify departures from ethical conduct. Any business which attended only to the needs of humanity without reference to the financial return would be liable to financial difficulties which might well prove insuperable. Nor will any socialization or nationalization of pharmaceutical research make much difference to this situation. The costs of research are inescapable, whoever bears them. In the nature of things it is probably better to devote principal resources to that which will be of maximum human benefit. How far a new research project will depend upon rational and how far upon speculative studies depends very much on the state of the art and on the qualities of the research workers involved. I have said enough to indicate my strong preference for rational design and to give some reason for thinking that it is more economical. In Lord Rutherford's words, ' We hadn't much money so we had to use our brains'. The biggest single problem to be solved at present is how to acquire a better understanding of the difference in responses of different species. Preliminary work on the discovery of drugs is likely always to be done on experimental animals, and the sooner we know those stiuations in which an experimental animal's responses can be trusted to predict what would happen in man and those circumstances in which they are misleading, the sooner we shall be in a position to use experimental data more satisfactorily. Moreover, it is important to realize how many new drugs have been discovered as a result of chance clinical observation in man; phenylbutazone (Gsell & Muller 1950) , monoamine oxidase inhibitors, imipramine (Kuhn 1957) and related antidepressants all spring to mind as examples of substances which were recognized as therapeutically useful because they had been given to man for some different purpose. We are still a long way from the rational design of drugs and every help that can be given by clinical observation of the unexpected potential therapeutic finding is perhaps more valuable than what can be achieved in any other way.
